Decreased linezolid uptake in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant.

OBJECTIVES The aim of this study was to characterize the mechanism of resistance to linezolid in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant. METHODS A linezolid-resistant strain of S. epidermidis was selected by serial passages with increasing concentrations of linezolid. The MICs of linezolid, ciprofloxacin, tetracycline, rifampicin, vancomycin, gentamicin, tobramycin, chloramphenicol and oxacillin were determined. The 23S rRNA gene was amplified and sequenced, to search for mutations conferring linezolid resistance. The MIC of linezolid was also determined in the presence of reserpine. Finally, the accumulation of linezolid was measured and quantified by HPLC/UV. RESULTS The obtained resistant strain had an MIC of linezolid of 64 mg/L and was stable after several passages on blood agar. The MIC measured in the presence of 25 mg/L reserpine, an efflux pump inhibitor, was not altered (MIC of 64 mg/L). The sequence of the 23S rRNA gene showed that the mutation G2576T (Escherichia coli numbering) was not present and no other mutation was found. An analysis of the accumulation of linezolid was performed, comparing the uptake of the resistant strain with that of the susceptible one. This showed that the resistant strain had significantly lower levels of linezolid accumulation than its susceptible parental strain. CONCLUSIONS The mechanism of resistance to linezolid, in this resistant strain, may be related to a decrease in the antimicrobial uptake. This new mechanism of resistance was also related to a little loss of fitness.

[1]  Ronald N. Jones,et al.  First Report of cfr-Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States , 2008, Antimicrobial Agents and Chemotherapy.

[2]  T. Wichelhaus,et al.  Linezolid Resistance in Staphylococcus aureus: Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances , 2008, Antimicrobial Agents and Chemotherapy.

[3]  Jaime Moreno,et al.  Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA Methyltransferase , 2008, Journal of Clinical Microbiology.

[4]  M. Ruiz,et al.  Importance of the Efflux Pump Systems in the Resistance of Mycobacterium tuberculosis to Fluoroquinolones and Linezolid , 2007, Chemotherapy.

[5]  J. Pagés,et al.  Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. , 2007, The Journal of antimicrobial chemotherapy.

[6]  S. North,et al.  In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci , 2007, Antimicrobial Agents and Chemotherapy.

[7]  W. Kern,et al.  Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. , 2006, The Journal of antimicrobial chemotherapy.

[8]  B. Bozdoğan,et al.  Oxazolidinones: activity, mode of action, and mechanism of resistance. , 2004, International journal of antimicrobial agents.

[9]  G. Eliopoulos,et al.  Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. , 2002, The Journal of infectious diseases.

[10]  L. Rice,et al.  Gene Dosage and Linezolid Resistance in Enterococcus faecium and Enterococcus faecalis , 2002, Antimicrobial Agents and Chemotherapy.